A recent comprehensive study has uncovered the significant health benefits and potential drawbacks of Ozempic and Wegovy. Groundbreaking research has shown that weight loss medications, such as Glucagon-like peptide-1 receptor agonists (GLP-1RA) like Ozempic and Wegovy, can have a total of 61 effects on the body, most of which are positive.
These drugs function by imitating the hormones naturally created in the body to regulate appetite, thereby promoting a sense of fullness and reducing hunger.
“Given the novelty and increasing popularity of these medications, it is crucial to thoroughly investigate their effects on various bodily systems to gain a comprehensive understanding of their benefits and risks,” said the study’s lead researcher, Dr. Ziyad Al Ali, an Assistant Professor at the School of Medicine, University of Washington, USA.
The research team, led by Al-Aly, discovered that these weight loss drugs could lower the risk of 42 health conditions while increasing the risk of 19 others.
The Positive Effects of Weight Loss Drugs
Published in Nature Medicine, the study analyzed data from 2 million individuals with diabetes, with approximately 216,000 using GLP-1RAs and the rest on other diabetes medications that do not include GLP-1RAs. The results suggested numerous health benefits for those using weight loss drugs, including a decreased risk of cardiovascular issues like blood clots, heart attacks, and strokes, aligning with previous research findings.
Additionally, beyond the known benefits, researchers discovered potential advantages in unexpected areas. Despite concerns about GLP-1RAs potentially causing suicidal thoughts, new research found positive impacts on neurological health. Users experienced reduced risks of conditions such as suicidal ideation, self-harm, substance use disorders, psychotic disorders like schizophrenia, and bulimia.
Al-Aly proposed that the mechanisms responsible for weight loss could also influence these outcomes. The drugs act on brain receptors associated with impulse control, reward, and addiction, potentially explaining their efficacy in curbing appetite and addiction disorders.
Furthermore, individuals using these drugs were less prone to cognitive disorders like Alzheimer’s disease and dementia, likely due to reduced brain inflammation. They also exhibited lower risks of seizures, bacterial infections, and pneumonia.
Although these medications do not serve as cures (the researchers noted a 10-20% risk reduction for these conditions), the benefits, especially for conditions like dementia with limited treatment options, remain significant.
The Hidden Risks of Weight Loss Drugs
Despite the numerous potential benefits of GLP-1RA drugs, there are also associated risks. Users showed increased susceptibility to gastrointestinal issues such as nausea, vomiting, abdominal pain, low blood pressure, and arthritis. Surprisingly, researchers identified a heightened risk of rare but severe pancreatic and kidney diseases.
“GLP-1RA drugs offer a wide array of health benefits,” Al Ali stated. “However, they are not without risks. Our findings underscore the importance of monitoring these drugs closely due to their broad usage and potential risks.” He emphasized the need for caution.
While the results could guide clinical care, some researchers raised concerns about the study’s design not considering other potential effects. They cautioned that interpretation should proceed with care, as the differences between individuals using GLP-1RAs like Ozempic and those who do not may stem from factors beyond the drug itself.
“Studies like this should be approached with caution, as individuals were not randomly assigned to GLP-1RA treatment,” explained Professor Stephen O’Rahilly, Director of the Wellcome MRC Metabolism Laboratory at the Metabolism Research Institute in Cambridge. He further stated that while the study provides reassurance on the drugs’ safety, caution remains necessary.
The researchers from the University of Washington recognized that their findings only observed associations and did not prove causation for the benefits or risks of GLP-1RAs. Additionally, the study participants primarily comprised older white men, indicating a need for future research to encompass a more diverse population.
Despite this limitation, the findings anticipate future research targeting a broader demographic. O’Rahilly suggested that the results offer reassurance regarding the risk/benefit balance of long-term GLP-1RA use in diabetic patients, creating anticipation for forthcoming investigations.
Comprehensive List of GLP-1RA Effects
Positive Effects
The study revealed that drugs like Ozempic could significantly reduce the risk of 42 health conditions, including:
- shock
- aspiration pneumonia
- liver failure
- respiratory failure
- cardiac arrest
- Bulimia
- schizophrenia
- pulmonary hypertension
- Postoperative respiratory complications
- liver cancer
- sepsis
- stimulant use disorder
- pneumonia
- Thromboembolic disorders
- pleural effusion
- hemorrhagic stroke
- chronic phlebitis
- opioid use disorder
- inflammatory bowel disease
- cannabis use disorder
- bacterial infection
- acute pulmonary embolism
- acute kidney injury
- Aftereffects after thrombosis
- pneumonia
- heart failure
- gangrene
- alcohol use disorder
- suicidal thoughts
- seizure
- Chronic obstructive pulmonary disease
- osteomyelitis
- myocardial infarction
- muscle pain
- heat
- deep vein thrombosis
- Coagulopathy and clotting disorders
- ischemic stroke
- Neurocognitive disorders
- urinary tract infection
- chronic kidney disease
- anemia
Negative Effects
The study also indicated a heightened risk of 19 health conditions associated with drugs like Ozempic, including:
- nausea and vomiting
- Non-infectious gastroenteritis
- sleep disorders
- abdominal pain
- Reflux esophagitis
- nephrolithiasis
- headache
- Tendonitis and synovitis
- joint pain
- arthritis
- gastritis
- hemorrhoids
- Diverticulosis and diverticulitis
- bone pain
- gastroparesis
- syncope
- interstitial nephritis
- low blood pressure
- osteoarthritis
Read more:
Source: www.sciencefocus.com
